Leslie A. Brun resigns from Merck’s board of directors
KENILWORTH, New Jersey – (COMMERCIAL THREAD) – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that Leslie A. Brun, its lead independent director, has resigned from its board of directors , effective August 19, 2021. Mr. Brun is stepping down due to his decision to become President and CEO of Ariel Alternatives, LLC, a subsidiary of Ariel Investments, LLC, an ongoing private equity initiative Creation to help evolve minority-owned businesses to serve as Tier 1 suppliers to Fortune 500 companies. Merck is currently evaluating an investment with Ariel Alternatives.
“Les has been an invaluable member of the Merck Board of Directors for many years and we have benefited greatly from his leadership, wise counsel and friendship, ”said Rob Davis, Managing Director and President of Merck. “Although he will be missed, we recognize the importance of the work Les undertakes at Ariel Alternatives, and we wish him every success.
The company intends to appoint a new independent lead director in the near future.
For 130 years, Merck, known as MSD outside of the United States and Canada, has invented for life, providing drugs and vaccines for many of the world’s most difficult diseases as part of our mission to save and improve lives. We demonstrate our commitment to patients and the health of the population by increasing access to health care through broad policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten humans and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – so that we aspire to be the leading research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and contact us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-looking statement by Merck & Co., Inc., Kenilworth, NJ, United States
This press release from Merck & Co., Inc., Kenilworth, NJ, United States (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act. from 1995. These statements are based on the current beliefs and expectations of the management of the company and are subject to significant risks and uncertainties. If the underlying assumptions prove to be incorrect or if risks or uncertainties materialize, actual results may differ materially from those stated in forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including fluctuations in interest rates and exchange rates; the impact of the global novel coronavirus disease (COVID-19) epidemic; the impact of pharmaceutical industry regulation and health care legislation in the United States and globally; global trends towards containing health care costs; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of patents and other corporate protections for innovative products; and exposure to litigation, including patent litigation, and / or regulatory actions.
The company does not undertake to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in forward-looking statements can be found in the Company’s 2020 Annual Report on Form 10-K and other documents filed by the Company with the Securities. and Exchange Commission (SEC) available from the SEC. Website (www.sec.gov).